{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:16Z","timestamp":1789578316084,"version":"build-2803163510"},"reference-count":8,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.04.005","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T19:50:13Z","timestamp":1777751413000},"page":"756-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SBRT for High-risk Localised Prostate Cancer: SHARP and the Limits of Non-randomised Evidence"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-9567","authenticated-orcid":false,"given":"Peter J.","family":"Hoskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.04.005_b0005","doi-asserted-by":"crossref","unstructured":"Valle LF, Romero-Kalbasi T, Jiang T, et al. Extended follow-up from the Stereotactic Body Radiotherapy for High-Risk Localised Carcinoma of the Prostate (SHARP) Consortium: updated analysis of 440 patients. Eur Urol Oncol 2026;9:860\u2013867.","DOI":"10.1016\/j.euo.2026.03.019"},{"key":"10.1016\/j.euo.2026.04.005_b0010","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients","volume":"110","author":"van Dams","year":"2021","journal-title":"Int J Radiat Oncol *Biol* Phys"},{"key":"10.1016\/j.euo.2026.04.005_b0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.04.005_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.6871","article-title":"Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: a patient-level data analysis of 3 cohorts","volume":"8","author":"Kishan","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.04.005_b0025","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.04.005_b0030","article-title":"PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT","volume":"58","author":"Pathmanathan","year":"2026","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.euo.2026.04.005_b0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034623","article-title":"Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)","volume":"10","author":"Murthy","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.euo.2026.04.005_b0040","unstructured":"NRG0013\/HIGH-five. Conventional\/moderately hypofractionated radiotherapy versus SBRT for high-risk prostate cancer. ClinicalTrials.gov identifier: NCT05946213 (accessed 21 March 2026)."}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:47:10Z","timestamp":1789577230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126001100"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SBRT for High-risk Localised Prostate Cancer: SHARP and the Limits of Non-randomised Evidence","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}